Free Trial
NASDAQ:IDN

Intellicheck (IDN) Stock Price, News & Analysis

Intellicheck logo
$2.30 +0.04 (+1.55%)
As of 12:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Intellicheck Stock (NASDAQ:IDN)

Advanced

Key Stats

Today's Range
$2.26
▼
$2.31
50-Day Range
$2.26
▼
$3.93
52-Week Range
$2.24
▼
$9.08
Volume
60,083 shs
Average Volume
361,406 shs
Market Capitalization
$46.52 million
P/E Ratio
15.30
Dividend Yield
N/A
Price Target
$6.50
Consensus Rating
Moderate Buy

Company Overview

Intellicheck, Inc. (NASDAQ: IDN) provides identity validation and fraud-prevention technology. Its platform is designed to authenticate government-issued identification documents, including driver’s licenses and other forms of identification, using mobile devices and application programming interfaces (APIs).

The company’s solutions support customer onboarding, know-your-customer and compliance processes, age verification, account opening, fraud detection, and identity authentication. Intellicheck serves organizations such as financial institutions, retailers, telecommunications companies, government agencies, and other businesses that need to verify identities remotely or at the point of service.

Intellicheck has developed its business around real-time document validation and identity verification, with services available through cloud-based and integrated technology solutions. The company was previously associated with the name Intellicheck Mobilisa before adopting the Intellicheck name as its focus became centered on identity authentication and fraud prevention.

AI Generated. May Contain Errors.

Intellicheck Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

IDN MarketRank™: 

Intellicheck scored higher than 51% of companies evaluated by MarketBeat, and ranked 353rd out of 597 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Intellicheck has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    Intellicheck has a consensus price target of $6.50, representing about 182.6% upside from its current price of $2.30.

  • Amount of Analyst Coverage

    Intellicheck has only been the subject of 3 research reports in the past 90 days.

  • Read more about Intellicheck's stock forecast and price target.
  • Earnings Growth

    Earnings for Intellicheck are expected to remain at $0.10 per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intellicheck is 15.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intellicheck is 15.33, which means that it is trading at a less expensive P/E ratio than the Technology sector average P/E ratio of about 82.03.

  • Price to Book Value per Share Ratio

    Intellicheck has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.87% of the float of Intellicheck has been sold short.
  • Short Interest Ratio / Days to Cover

    Intellicheck has a short interest ratio ("days to cover") of 3.32, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Intellicheck has recently decreased by 0.21%, indicating that investor sentiment is improving.
  • Dividend Yield

    Intellicheck does not currently pay a dividend.

  • Dividend Growth

    Intellicheck does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Intellicheck this week, compared to 2 articles on an average week.
  • Search Interest

    Only 5 people have searched for IDN on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Intellicheck insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.76% of the stock of Intellicheck is held by insiders.

  • Percentage Held by Institutions

    42.79% of the stock of Intellicheck is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Intellicheck's insider trading history.
Receive IDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellicheck and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDN Stock News Headlines

Intellicheck (NASDAQ:IDN) Stock Rating Raised to Buy at Wall Street Zen
FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial
A NASDAQ-listed biotech just cleared a major regulatory milestone. The FDA has cleared its lead multiple sclerosis therapy, Lucid-MS, to enter Phase 2 clinical trials - the first time it will be tested in patients with progressive MS. Unlike treatments that suppress the immune system, Lucid-MS is designed to protect myelin, the insulating layer destroyed by the disease. In a pre-clinical mouse model, treatment led to movement recovery including walking. Independent research projects peak annual sales of up to $5 billion if Phase 2 succeeds. The stock still trades under $5 per share.tc pixel
Intellicheck, Inc. (IDN) Q2 2026 Earnings Call Transcript
Intellicheck Reports Second Quarter 2026 Results
See More Headlines

IDN Stock Analysis - Frequently Asked Questions

Intellicheck's stock was trading at $6.68 at the beginning of 2026. Since then, IDN stock has decreased by 65.6% and is now trading at $2.30.

Intellicheck, Inc. (NASDAQ:IDN) issued its quarterly earnings data on Thursday, August, 13th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. The firm earned $5.94 million during the quarter. Intellicheck had a net margin of 13.03% and a trailing twelve-month return on equity of 15.02%.
Read the conference call transcript
.

Intellicheck's stock reverse split on Wednesday, August 13th 2014.The 1-8 reverse split was announced on Tuesday, August 12th 2014. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 12th 2014. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of IDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intellicheck investors own include Pfizer (PFE), Vale (VALE), Meta Platforms (META), NVIDIA (NVDA), NIO (NIO), Ford Motor (F) and Micron Technology (MU).

Company Calendar

Last Earnings
8/13/2026
Today
10/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Software
Sub-Industry
Application Software
Current Symbol
NASDAQ:IDN
Previous Symbol
NYSE:IDN
CIK
1040896
Employees
38
Year Founded
N/A

Price Target and Rating

High Price Target
$8.50
Low Price Target
$5.00
Potential Upside/Downside
+183.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.15
Trailing P/E Ratio
15.30
Forward P/E Ratio
22.95
P/E Growth
N/A
Net Income
$1.27 million
Net Margins
13.03%
Pretax Margin
13.27%
Return on Equity
15.02%
Return on Assets
12.27%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.98
Quick Ratio
4.98

Sales & Book Value

Annual Sales
$22.67 million
Price / Sales
2.05
Cash Flow
$0.10 per share
Price / Cash Flow
23.21
Book Value
$1.02 per share
Price / Book
2.25

Miscellaneous

Outstanding Shares
20,270,000
Free Float
18,694,000
Market Cap
$46.52 million
Optionable
N/A
Beta
0.79
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:IDN) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners